Stem Cell Beta Cell Differentiation Using Metabolite Regulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The limited supply of pancreatic islets from donor tissue hinders the effectiveness of pancreatic islet transplantation for diabetes treatment, necessitating improved methods for generating implantable islets from alternative sources such as stem cells.
Innovation Solution
The development of compositions and methods for in vitro production of SC-β cells using PDX1-positive, NKX6.1-positive, insulin-negative cells with specific metabolites like acetate, glutamine, and HDAC inhibitors to enhance cell yields, stability, and functionality, resulting in improved SC-islet clusters with reduced size and increased uniformity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If pancreatic islet transplantation is used to treat diabetes, then clinical benefit is achieved, but the limited supply of donor pancreatic islets prevents effective implementation
Solution Approach 1:
The patent creates copies of pancreatic islet cells by differentiating stem cells into beta cells that replicate the function of natural islet cells. This allows production of multiple functional islet equivalents from a single stem cell source, effectively copying the therapeutic benefit without requiring additional donor tissue.
Solution Approach 2:
The patent changes the source parameter from donor pancreatic tissue to stem cells, and optimizes differentiation conditions including metabolite concentrations (acetate, beta-hydroxybutyrate, taurine, formate), HDAC inhibitor levels, and redox homeostasis regulators to maximize beta cell yield and functionality.
2Adaptability or versatility
If stem cells are used to generate implantable islets, then alternative source is provided, but cell yields and functionality need improvement
Solution Approach 1:
The patent systematically optimizes biochemical parameters including metabolite concentrations (acetate 0.1-10mM, beta-hydroxybutyrate 0.1-5mM, taurine 0.1-5mM, formate 0.1-5mM), HDAC inhibitor levels (0.01-10 µM), and redox regulators to maximize stem cell differentiation efficiency and beta cell yield.
Solution Approach 2:
The patent uses intermediate compounds including metabolites that fuel cellular metabolism, HDAC inhibitors that modulate gene expression, and redox homeostasis regulators that protect cellular health during differentiation, thereby improving overall productivity of beta cell generation.
3Ease of manufacture
If SC-β cells are produced for therapeutic use, then diabetes treatment is enabled, but immunogenicity after transplantation must be reduced
Solution Approach 1:
The patent optimizes culture conditions including metabolite concentrations, pH levels, oxygen tension, and differentiation timing to produce beta cells with reduced immunogenicity while maintaining therapeutic functionality, enabling easier manufacturing of transplantable cell products.
4Productivity
If in vitro production methods are developed, then large scale manufacture is enabled, but manufacturing precision and cell uniformity must be improved
Solution Approach 1:
The patent establishes precise parameter ranges for metabolite concentrations, inhibitor levels, and culture conditions that ensure consistent beta cell differentiation across large-scale production, achieving both high productivity and manufacturing precision.
Solution Approach 2:
The patent uses homogeneous culture conditions and standardized differentiation protocols to produce uniform populations of beta cells with consistent functional characteristics, enabling reliable large-scale manufacture for clinical use.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These methods lead to higher cell yields, improved viability, and reduced immunogenicity of SC-β cells, enabling their large-scale manufacture for therapeutic use in diabetes treatment.
Implementation Method 1
contacting the PDX1-positive, NKX6.1-positive cells with a composition comprising one or more of an acetyl CoA related metabolite, an HDAC inhibitor, a redox homeostasis regulator, or a one carbon metabolism pathway intermediate
Implementation Method 2
contacting the PDX1-positive, NKX6.1-positive cells with a composition comprising one or more of an acetyl CoA related metabolite, an HDAC inhibitor, a redox homeostasis regulator, or a one carbon metabolism pathway intermediate
Data Source
AI summary
Provided herein are, inter alia, compositions and methods for improved production of SC-β cells in vitro. For example, provided are novel formulations and differentiation methods that result in higher cell yields and recoveries, increased numbers and relative percentages of SC-β cells, enhanced stability and shelf-life of SC-β cells, SC-islet clusters with advantageous characteristics such as reduced size and increased uniformity, improved function of the SC-β cells in vitro, and improved viability, function, and reduced immunogenicity after transplantation. The disclosed compositions and methods can be employed in the manufacture of SC-islets for human therapeutic use.